IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Prostate cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms IMPACT
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 29 Oct 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Aug 2018 to 1 Nov 2018.
- 11 Sep 2018 Status changed from not yet recruiting to recruiting.